This title appears in the Scientific Report :
2010
Please use the identifier:
http://dx.doi.org/10.1016/j.nucmedbio.2010.04.185 in citations.
Fluorine-18 radiopharmaceuticals (beyond [18F]FDG) for use in oncology and neurosciences
Fluorine-18 radiopharmaceuticals (beyond [18F]FDG) for use in oncology and neurosciences
Positron emission tomography (PET) is a rapidly expanding clinical modality worldwide thanks to the availability of compact medical cyclotrons and automated chemistry for the production of radiopharmaceuticals. There is an armamentarium of fluorine-18 ((18)F) tracers that can be used for PET studies...
Saved in:
Personal Name(s): | Coenen, H. H. |
---|---|
Elsinga, P.H. / Iwata, R. / Kilbourn, M.R. / Pillai, M.R.A. / Rajan, M.G.R. / Wagner, H.N. / Zaknun, J. | |
Contributing Institute: |
Nuklearchemie; INM-5 JARA-BRAIN; JARA-BRAIN |
Published in: | Nuclear medicine and biology, 37 (2010) S. 727 - 740 |
Published in: |
Report of an IAEA Consultants Group Meeting |
Imprint: |
Amsterdam [u.a.]
Elsevier
2010
|
Physical Description: |
727 - 740 |
PubMed ID: |
20870148 |
DOI: |
10.1016/j.nucmedbio.2010.04.185 |
Document Type: |
Journal Article |
Research Program: |
(Dys-)function and Plasticity Funktion und Dysfunktion des Nervensystems |
Series Title: |
Nuclear Medicine and Biology
37 |
Subject (ZB): | |
Publikationsportal JuSER |
Positron emission tomography (PET) is a rapidly expanding clinical modality worldwide thanks to the availability of compact medical cyclotrons and automated chemistry for the production of radiopharmaceuticals. There is an armamentarium of fluorine-18 ((18)F) tracers that can be used for PET studies in the fields of oncology and neurosciences. However, most of the (18)F-tracers other than 2-deoxy-2-[18F]fluoro-D-glucose (FDG) are in less than optimum human use and there is considerable scope to bring potentially useful (18)F-tracers to clinical investigation stage. The International Atomic Energy Agency (IAEA) convened a consultants' group meeting to review the current status of (18)F-based radiotracers and to suggest means for accelerating their use for diagnostic applications. The consultants reviewed the developments including the synthetic approaches for the preparation of (18)F-tracers for oncology and neurosciences. A selection of three groups of (18)F-tracers that are useful either in oncology or in neurosciences was done based on well-defined criteria such as application, lack of toxicity, availability of precursors and ease of synthesis. Based on the recommendations of the consultants' group meeting, IAEA started a coordinated research project on "Development of (18)F radiopharmaceuticals (beyond [(18)F]FDG) for use in oncology and neurosciences" in which 14 countries are participating in a 3-year collaborative program. The outcomes of the coordinated research project are expected to catalyze the wider application of several more (18)F-radiopharmaceuticals beyond FDG for diagnostic applications in oncology and neurosciences. |